CN103385913A - Radix Astragali extract and its preparation method and preparation - Google Patents
Radix Astragali extract and its preparation method and preparation Download PDFInfo
- Publication number
- CN103385913A CN103385913A CN2013103025684A CN201310302568A CN103385913A CN 103385913 A CN103385913 A CN 103385913A CN 2013103025684 A CN2013103025684 A CN 2013103025684A CN 201310302568 A CN201310302568 A CN 201310302568A CN 103385913 A CN103385913 A CN 103385913A
- Authority
- CN
- China
- Prior art keywords
- radix astragali
- parts
- preparation
- tablet
- astragali extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines and relates to Radix Astragali extract and its preparation method and preparation. The Radix Astragali extract is used for treating shortness of breath, palpitaition, collapse, spontaneous perspiration, asthenia and edema, symptoms after tumor chemoradiotherapy and operation, chronic nephrosis, chronic diarrhea, proctoptosia, uterine prolapsed, gynecological diseases, ulcer fester and nonunion wounds. The Radix Astragali extract has obviously improved content of total saponins and astragaloside. The preparation method comprises the following steps of adding water into Radix Astragali, carrying out decoction, filtering the decoction, concentrating the filtrate, adding ethanol into the concentrated filtrate, carrying out standing, collecting a supernatant, recovering the ethanol, carrying out condensation and drying, and carrying out crushing to obtain fine powder. Aiming at solving defects of the existing preparation and satisfying clinical medicine requirements, the inventor carries out detailed research. The Radix Astragali extract as an active component and appropriate medicinal auxiliary materials are processed into the preparation by the conventional processes.
Description
Technical field
The invention belongs to the field of Chinese medicines, relate to a kind of Radix Astragali extract and preparation method thereof and preparation, specifically be applied to the cardiopalmus of breathing hard, collapse, spontaneous perspiration, body is impractical swollen, after tumor chemoradiotherapy and operation, and chronic nephropathy, chronic diarrhea, proctoptosis, uterine prolapse, gynaecopathia, carbuncle is difficult bursts, the diseases such as open sore part disunion of a specified duration.
Background technology
The Radix Astragali, have another name called Radix Astragali, mainly be distributed in Yanshan mountain range, Mount Taishan, Xiaowutai Shan Mountain, Hengshan Mountain, Wutai Mountain, loess plateau, Tai Yueshan, the Qinling Mountains, the areas such as the north of Hengduan mountain range in Xing'anling mountains, Wanda Mountain, Zhang Guangcai mountain range, master mountain range, Changbai Mountain and Mountainous Region in Eastern Liaoning and North China in Altai Mountains, the northeast of Xinjiang of China.The Chinese crude drug Radix Astragali records according in one one of Pharmacopoeia of the People's Republic of China version in 2010: the Radix Astragali is the dry root of leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge.var.mongholicus (Bge.) Hsiao or Radix Astragali Astragalus membranaceus (Fisch.) Bge., have tonifying Qi and lifting yang, strengthening superficial resistance to stop perspiration, inducing diuresis to remove edema, promote the production of body fluid nourish blood, the effects such as the stagnant blood stasis dispelling of row, detoxification evacuation of pus, expelling pus and promoting granulation.The medicinal history of existing more than 2000 year so far of the Radix Astragali, modern study shows, the Radix Astragali contains the various trace elements such as saponin, sucrose, polysaccharide, several amino acids, folic acid and selenium, zinc, copper, its pharmacologically active is varied, cardiovascular system there is many-sided effect, also have simultaneously antitumor, improve body's immunity and reduce the functions such as blood glucose, blood pressure lowering, endocrine regulation, thereby application is very extensive, and more and more be subject to people's attention.
The Radix Astragali cures mainly according to its function, is medium-term and long-term medication, and traditional instructions of taking is decoction, operates comparatively loaded down with trivial detailsly, and not portable, so modern industry is made into preparation, conveniently uses and carries.At present the preparation of the folk prescription Radix Astragali is mainly granule, tablet, injection etc., and Milkvetch Root is made preparation, Milkvetch Root must be extracted and be prepared into Radix Astragali extract therebetween, then add the required adjuvant of various preparations etc. to be prepared as all types of preparations.
Concentrate, be drying to obtain after the preparation method of Radix Astragali extract is mainly common water extraction, alcohol extraction or water extract-alcohol precipitation at present, in the gained Radix Astragali extract, the content of significant composition Radix Astragali total saponins is generally below 20mg/g, Astragaloside content is generally on the low side, is generally below 1mg/g.The present invention wants to provide a kind of new Radix Astragali extract and preparation method thereof and preparation, this extracting method can significantly improve the content of Radix Astragali total saponins, and its preparation can be significantly improved disintegration, and preparation Radix Astragali total saponins and the Astragaloside content of same formula are higher.
Summary of the invention
Technical problem solved by the invention is to provide a kind of new Radix Astragali extract, and this extract total saponin content and Astragaloside content are significantly increased.
Radix Astragali extract of the present invention adopts following method preparation:
A, get the Radix Astragali and add and extract solvent and decoct 2-4 time, add water 8-12 at every turn and doubly measure, decoct 1-3 hour, collecting decoction, filtration at every turn;
Wherein, described extraction solvent is to be regulated the aqueous solution of pH value to 9～10 by the mixture of sodium hydrogen phosphate, tertiary sodium phosphate, and the weight proportion of sodium hydrogen phosphate, tertiary sodium phosphate is 1:2～1:1;
It is 1.10～1.30(70-90 ℃ that B, filtrate are concentrated into relative density) the clear paste I, add ethanol and make the alcohol amount of containing be 60-80%, stir evenly, standing;
C, get supernatant and reclaim ethanol, being concentrated into relative density is 1.20～1.35(70-90 ℃) the clear paste II, drying;
D, clear paste II are ground into fine powder, and carry out micronization, obtain; The preferred D95=8 of micronization particle size range～15 μ m.
Further preferred extraction conditions:
1) decoct with water number of times in steps A preferred 2 times, the preferred 10 times of amounts of amount of water.
2) in step B, the clear paste I is added ethanol and is preferably made and contain the alcohol amount and reach 70%.
3) decocting liquid in step B, filter, and the concentrated preferred relative density of gained clear paste I of filtrate is 1.15～1.20(80 ℃).
4) get supernatant in step C and reclaim ethanol, the concentrated preferred relative density of gained clear paste II is 1.25～1.30(80 ℃).
5) in step B and step C, method for concentration can adopt any one in the methods such as concentrating under reduced pressure, Multi-effect concentration, membrane separation technique.
6) in step C, drying means can adopt any one in spray drying, vacuum belt type drying or drying under reduced pressure.If employing drying under reduced pressure, condition can be controlled in 70 ℃ ,-0.07MPa.
Through experiment results proved, this extraction process gained Radix Astragali extract total saponins, Astragaloside content are all higher, prove the better effects if of Radix Astragali extract of the present invention through animal test results.
Further, also above-mentioned Radix Astragali extract can be added suitable pharmaceutic adjuvant, preparation process routinely is prepared into active constituent content and the higher various preparations of bioavailability, described preparation is mainly various oral formulations, as tablet, granule, capsule, drop pill or oral liquid etc.Described tablet is ordinary tablet, oral cavity disintegration tablet, chewable tablet, effervescent tablet, enteric coatel tablets, dispersible tablet, slow releasing tablet or controlled release tablet; Described ordinary tablet is sugar coated tablet or thin film tablet.
Through inventor's primary study, with Radix Astragali extract of the present invention make ordinary tablet, dispersible tablet can more convenient more effective meeting clinical needs.Radix Astragali extract ordinary tablet of the present invention and dispersible tablet have advantages of all that disintegration rate is fast, total saponins and Astragaloside content high.
While preparing the ordinary tablet of Radix Astragali extract of the present invention, the sheet heart is prepared from by the component of following weight proportion:
300～450 parts of Radix Astragali extracts, 20～30 parts of starch, 2～4 parts of magnesium stearate.
The preferred weight proportioning is: 350～400 parts of Radix Astragali extracts, 24～28 parts of starch, 2～3 parts of magnesium stearate.
Most preferably weight proportion is: 380 parts of Radix Astragali extracts, 28 parts of starch, 2 parts of magnesium stearate.
The sheet heart of above-mentioned ordinary tablet further sugar coating or film-coat is made sugar coated tablet or thin film tablet.
While preparing the dispersible tablet of Radix Astragali extract of the present invention, the sheet heart is prepared from by the component of following weight proportion:
250～400 parts of Radix Astragali extracts, 50～120 parts of microcrystalline Cellulose, 60～120 parts of carboxymethyl starch sodium, 10～20 parts of crospolyvinylpyrrolidone, 3～8 parts of magnesium stearate.
Further the preferred weight proportioning is: 330～380 parts of Radix Astragali extracts, 75～110 parts of microcrystalline Cellulose, 70～110 parts of carboxymethyl starch sodium, 10～15 parts of crospolyvinylpyrrolidone, 3～7 parts of magnesium stearate.
Most preferably weight proportion is: 360 parts of Radix Astragali extracts, 90 parts of microcrystalline Cellulose, 100 parts of carboxymethyl starch sodium, 10 parts of crospolyvinylpyrrolidone, 5 parts of magnesium stearate.
The specific embodiment
The specific embodiment of form, be described in further detail foregoing of the present invention again by the following examples, illustrates but do not limit the present invention.
The comparative example 1: the existing report of astragalus mongholicus tablet is pressed the method preparation of CN200510022192.7 record.
Get Radix Astragali 3750g, decoct with water 1-6 time, 2-3 hour, add water 10-15 times water gaging for the first time, 1-2 hour, add water 8-16 times water gaging for the second time, and collecting decoction filters, filtrate decompression is concentrated into relative density and is about 1.26～1.30(50 ℃) clear paste, add ethanol and make that to contain alcohol amount be 70%, stir evenly, standing, get supernatant and reclaim ethanol, being concentrated into relative density is 1.20～1.50(38 ℃) clear paste, add right amount of auxiliary materials, mix, granulate, cold drying, be pressed into 1000, film coating, obtain.
According to appendix XII A inspection technique disintegration of Chinese Pharmacopoeia version in 2010, formulation samples being carried out disintegration investigates:
Take astragaloside as contrast, adopt sulphuric acid-vanillin solution colorimetry, measure Radix Astragali total saponins content in extract and formulation samples according to appendix V A ultraviolet visible spectrophotometry of Chinese Pharmacopoeia version in 2010.
Take astragaloside as contrast, according to the content of astragaloside in Chinese Pharmacopoeia appendix VI D high effective liquid chromatography for measuring extract of version in 2010 and formulation samples.
The results are shown in Table 1:
Table 1
The embodiment of the present invention 1 ordinary tablet
get Radix Astragali 3750g, add water (sodium hydrogen phosphate, the mixed solution of tertiary sodium phosphate 1:1 is regulated pH value to 9) the decoction secondary, add 10 times of water gagings at every turn, 3 hours for the first time, 2 hours for the second time, collecting decoction, filter, filtrate decompression is concentrated into relative density and is about 1.15(80 ℃) clear paste, add ethanol and make that to contain alcohol amount be 70%, stir evenly, standing, get supernatant and reclaim ethanol, being concentrated into relative density is 1.25(80 ℃) clear paste, at 70 ℃, drying under reduced pressure under-0.07MPa condition, be ground into fine powder, and be micronized to D95=10 μ m, obtain approximately 375g of Radix Astragali extract, add starch 24 grams, mix, granulate, add magnesium stearate 2 grams, mix, be pressed into 1000, film coating, obtain.
The embodiment of the present invention 2 ordinary tablets
get Radix Astragali 3750g, add water (sodium hydrogen phosphate, the mixed solution of tertiary sodium phosphate 1:1 is regulated pH value to 10) the decoction secondary, add 10 times of water gagings at every turn, 3 hours for the first time, 2 hours for the second time, collecting decoction, filter, filtrate decompression is concentrated into relative density and is about 1.17(80 ℃) clear paste, add ethanol and make that to contain alcohol amount be 70%, stir evenly, standing, get supernatant and reclaim ethanol, being concentrated into relative density is 1.26(80 ℃) clear paste, at 70 ℃, drying under reduced pressure under-0.07MPa condition, be ground into fine powder, and be micronized to D95=12 μ m, obtain approximately 380g of Radix Astragali extract, add starch 28 grams, mix, dry granulation, add magnesium stearate 2 grams, mix, be pressed into 1000, film coating, obtain.
The embodiment of the present invention 3 dispersible tablets
get Radix Astragali 3750g, add water (sodium hydrogen phosphate, the mixed solution of tertiary sodium phosphate 1:1 is regulated pH value to 9) the decoction secondary, add 10 times of water gagings at every turn, 3 hours for the first time, 2 hours for the second time, collecting decoction, filter, filtrate decompression is concentrated into relative density and is about 1.20(80 ℃) clear paste, add ethanol and make that to contain alcohol amount be 70%, stir evenly, standing, get supernatant and reclaim ethanol, being concentrated into relative density is 1.30(80 ℃) clear paste, at 70 ℃, drying under reduced pressure under-0.07MPa condition, be ground into fine powder, and be micronized to D95=9 μ m, obtain approximately 360g of Radix Astragali extract, add microcrystalline Cellulose 90g, mix, the alcoholic solution (5%) that adds the 10g crospolyvinylpyrrolidone, 24 orders are granulated, 60 ℃ of dryings, cross 24 mesh sieve granulate, add again carboxymethyl starch sodium 100g and magnesium stearate 5g, mix, be pressed into 1000, film coating, obtain.
According to appendix XII A inspection technique disintegration of Chinese Pharmacopoeia version in 2010, formulation samples being carried out disintegration investigates:
Take astragaloside as contrast, adopt sulphuric acid-vanillin solution colorimetry, measure Radix Astragali total saponins content in extract and formulation samples according to appendix V A ultraviolet visible spectrophotometry of Chinese Pharmacopoeia version in 2010.
Take astragaloside as contrast, according to the content of astragaloside in Chinese Pharmacopoeia appendix VI D high effective liquid chromatography for measuring extract of version in 2010 and formulation samples.
The extract of each embodiment and the preparation of three batches are carried out the These parameters investigation, the results are shown in Table 2:
Table 2
Below for the enhancing immunity zoopery of Radix Astragali extract tablet of the present invention:
Animal grouping and administration are divided into 5 groups at random with mice.Every group 40.Be respectively blank group, astragalus mongholicus tablet group I (comparative example 1), astragalus mongholicus tablet group II (embodiment 1), astragalus mongholicus tablet group III (embodiment 2), astragalus mongholicus tablet group IV (embodiment 3).Each group with normal saline dilution to stand-by concentration, standby.The gavage amount of every mice of astragalus mongholicus tablet group I is 733mg/kg, and the gavage amount of astragalus mongholicus tablet group II～every mice of IV matched group is 546mg/kg, gavage normal saline 1ml.Free choice feeding, continuous 30 days.
The detection general status observation that test detects index mouse growth situation and rate of body weight gain comprises chaeta, mental status, diet and active situation.Before on-test and on-test after every 10 days, survey 1 time Mouse Weight.
The mensuration of mouse immune organ index: after on-test 11,21,31 days respectively, take off neck after weighing and put to death mice, dissect, take out Thymus and spleen and divide the another name weight in wet base, then calculate the Thymus and spleen index.Thymus or index and spleen index one thymus weigh or heavy (the mg)/body weight (g) of spleen.
The detection of Mouse Blood cell quantity: 11,21,31 days mouse tail veins blood sampling 20ml after on-test respectively is placed in diluent, with blood counting instrument meter blood cell count.
The detection of mouse peripheral blood liquid IgG content is respectively at 11,21,31 days that test, mouse tail vein blood sampling 0.5mL, room temperature is placed 1h, solidification blood and tube wall are peeled off, serum is fully separated out,, then in the centrifugal 10min of 2000r/min, collect serum, adopt mouse IgG enzyme immunoassay (ELISA) test kit, by specification operates.
Each group difference of each test data application of date processing SPSS software analysis.
It is normal at test front and back food-intake, inflow that mice is respectively organized in the variation of result of the test mouse growth situation and rate of body weight gain,, by a hair gloss, movable good, reacts quick, illustrates that astragalus mongholicus tablet has no adverse effects to the mouse growth situation.Each is organized the mice rate of body weight gain and changes in Table 3.
The variation of table 3 test mice rate of body weight gain
Annotate: * represents significant difference (P＜0.05).
As shown in Table 3, with the blank group, compare, two test group all can significantly improve rate of body weight gain (P＜0.05), and astragalus mongholicus tablet group II～IV effect is more slightly good.
The variation of table 4 test mice immune organ (thymus) index
Annotate: * represents significant difference (P＜0.05).
As shown in Table 4,, on the impact of thymus organ index, with the blank group, compare, two test group all can significantly improve thymus index (P＜0.05), astragalus mongholicus tablet group II～IV better effects if.
The variation of table 5 test mice immune organ (spleen) index
Annotate: * represents significant difference (P＜0.05).
As shown in Table 5,, on the impact of index and spleen index, with the blank group, compare, two test group are improved, but all effect is not exclusively obvious, it seems that totally astragalus mongholicus tablet group II～IV is slightly good.
The variation of table 6 test mice quantity of leucocyte
As shown in Table 6,, on the impact of quantity of leucocyte, with the blank group, compare, not obviously impact of astragalus mongholicus tablet group I (P〉0.05); Astragalus mongholicus tablet group II～IV compares with blank group, and at 1l, 21,31d, difference is remarkable (P＜0.05) all, can significantly improve the leukocyte number.
The variation of table 7 test mice erythrocyte number
As shown in Table 7, on the impact of erythrocyte number, with the blank group relatively, astragalus mongholicus tablet group I～IV is significant difference (P＜0.05) when 11d, other times are without significantly affecting (P〉0.05).Illustrate that four groups of groups are not obvious to erythrocytic impact effect.
The variation of table 8 test mice IgG content
As shown in Table 8,, on the impact of IgG content, with the blank group, compare, each test group can significantly improve IgG content (P＜0.05), and astragalus mongholicus tablet group II～IV better effects if.
The extraction solvent pH value of Radix Astragali extract of the present invention and adjusting pH value agents useful for same kind and proportion are comparatively crucial technological parameters, below for adopting Radix Astragali extract of the present invention to extract the contrast test that the outer parameter of solvent prescribed limit is carried out, list each comparative sample in table 9 and extract the solvent pH value and regulate pH value agents useful for same kind and ratio, all the other prescriptions and technique are in full accord with embodiment 1.
Table 9
| The comparative sample sequence number | PH value | Reagent | Ratio of reagents |
| 1 | 8 | The mixture of sodium hydrogen phosphate, tertiary sodium phosphate | 1:1 |
| 2 | 11 | The mixture of sodium hydrogen phosphate, tertiary sodium phosphate | 1:1 |
| 3 | 6 | Phosphoric acid | —— |
| 4 | 9 | Sodium hydrogen phosphate | —— |
| 5 | 9 | Tertiary sodium phosphate | —— |
| 6 | 9 | Sodium hydroxide | —— |
Take astragaloside as contrast, adopt sulphuric acid-vanillin solution colorimetry, measure above-mentioned comparative sample extract Radix Astragali total saponins content according to appendix V A ultraviolet visible spectrophotometry of Chinese Pharmacopoeia version in 2010.
Take astragaloside as contrast, according to the content of the above-mentioned comparative sample extract of an appendix VI D high effective liquid chromatography for measuring astragaloside of Chinese Pharmacopoeia version in 2010.The results are shown in Table 10:
Table 10
| Sample | Radix Astragali total saponins content (mg/g) | Astragaloside content (C 41H 68O 14）(mg/g) |
| Comparative sample 1 | 19.79 | 1.11 |
| Comparative sample 2 | 20.41 | 1.36 |
| Comparative sample 3 | 17.68 | 0.97 |
| Comparative sample 4 | 21.69 | 1.31 |
| Comparative sample 5 | 22.17 | 1.38 |
| Comparative sample 6 | 22.45 | 1.27 |
Radix Astragali extract micropowder particle diameter of the present invention is also comparatively crucial technological parameter, below be the outer contrast test of Radix Astragali extract micropowder particle size range of the present invention, list each comparative sample micronization particle size range in table 11, all the other prescriptions and technique are in full accord with embodiment 1.
Table 11
| The comparative sample sequence number | 7 | 8 | 9 | 10 |
| Particle diameter | D95=6 | D95=7 | D95=16 | D95=17 |
According to appendix XII A inspection technique disintegration of Chinese Pharmacopoeia version in 2010, formulation samples being carried out disintegration investigates:
Take astragaloside as contrast, adopt sulphuric acid-vanillin solution colorimetry, measure Radix Astragali total saponins content in extract and formulation samples according to appendix V A ultraviolet visible spectrophotometry of Chinese Pharmacopoeia version in 2010.
Take astragaloside as contrast, according to the content of astragaloside in Chinese Pharmacopoeia appendix VI D high effective liquid chromatography for measuring extract of version in 2010 and formulation samples.
Each contrast test sample is carried out These parameters investigates, the results are shown in Table 12:
Table 12
Upper watch test as a result in contrast table 2 embodiment of the present invention result of the test can find out, the sample of Radix Astragali extract in micronization particle size range of the present invention is fast than the sample disintegration rate outside this particle size range, total saponins and Astragaloside content are high.
To sum up, adopt the total saponin content of extracting method gained Radix Astragali extract of the present invention and Astragaloside content to significantly improve than the comparative example is extract obtained, and prepare preparation disintegration and all significantly improvement of Astragaloside content of gained.From zoopery as seen, Radix Astragali extract of the present invention and prepare the gained tablet improving rate of body weight gain, improve thymus index, improve aspect the leukocyte number and all obviously be better than prior art.
Claims (10)
1. the preparation method of Radix Astragali extract is characterized in that step is as follows:
A, get the Radix Astragali and add and extract solvent and decoct 2-4 time, add water 8-12 at every turn and doubly measure, decoct 1-3 hour, collecting decoction, filtration at every turn;
It is 1.10～1.30(70-90 ℃ that B, filtrate are concentrated into relative density) the clear paste I, add ethanol and make the alcohol amount of containing be 60-80%, stir evenly, standing;
C, get supernatant and reclaim ethanol, being concentrated into relative density is 1.20～1.35(70-90 ℃) the clear paste II, drying;
D, clear paste II are ground into fine powder, and carry out micronization, obtain;
Wherein, the described extraction solvent of steps A is regulated the aqueous solution of pH value to 9～10 by the mixture of sodium hydrogen phosphate, tertiary sodium phosphate; The weight proportion of sodium hydrogen phosphate, tertiary sodium phosphate is 1:2～1:1;
The micronization particle size range is D95=8～15 μ m.
2. the preparation method of Radix Astragali extract according to claim 1, it is characterized in that: decocting with water number of times in steps A is 2 times, amount of water is 10 times of amounts.
3. the preparation method of Radix Astragali extract according to claim 1 is characterized in that:
In step B, the clear paste I is added ethanol and is preferably made and contain the alcohol amount and reach 70%;
Decocting liquid in step B, filter, and the concentrated preferred relative density of gained clear paste I of filtrate is 1.15～1.20(80 ℃).
4. the preparation method of Radix Astragali extract according to claim 1 is characterized in that: get supernatant in step C and reclaim ethanol, the concentrated preferred relative density of gained clear paste II is 1.25～1.30(80 ℃).
5. the preparation method of Radix Astragali extract according to claim 1, it is characterized in that: in step B and step C, method for concentration can adopt any one in concentrating under reduced pressure, Multi-effect concentration, membrane separation technique.
6. the preparation method of Radix Astragali extract according to claim 1, it is characterized in that: in step C, drying means is any one in spray drying, vacuum belt type drying or drying under reduced pressure.
7. the described method of claim 1-6 any one prepares the Radix Astragali extract of gained.
8. the preparation of Radix Astragali extract, is characterized in that:, take the described Radix Astragali extract of claim 7 as active component, add suitable pharmaceutic adjuvant, the preparation that preparation process is routinely made.
9. the preparation of Radix Astragali extract according to claim 8 is characterized in that:
Described preparation is oral formulations;
Described oral formulations preferred tablet, capsule, granule, drop pill or oral liquid;
The preferred ordinary tablet of described tablet, oral cavity disintegration tablet, chewable tablet, effervescent tablet, enteric coatel tablets, dispersible tablet, slow releasing tablet or controlled release tablet; Described ordinary tablet is sugar coated tablet or thin film tablet.
10. the preparation of Radix Astragali extract according to claim 9 is characterized in that:
The sheet heart of described ordinary tablet is prepared from by the component of following weight proportion:
300～450 parts of Radix Astragali extracts, 20～30 parts of starch, 2～4 parts of magnesium stearate;
The preferred weight proportioning is: 350～400 parts of Radix Astragali extracts, 24～28 parts of starch, 2～3 parts of magnesium stearate;
Most preferably weight proportion is: 380 parts of Radix Astragali extracts, 28 parts of starch, 2 parts of magnesium stearate;
The sheet heart of above-mentioned ordinary tablet further sugar coating or film-coat is made sugar coated tablet or thin film tablet;
The sheet heart of described dispersible tablet is prepared from by the component of following weight proportion:
250～400 parts of Radix Astragali extracts, 50～120 parts of microcrystalline Cellulose, 60～120 parts of carboxymethyl starch sodium, 10～20 parts of crospolyvinylpyrrolidone, 3～8 parts of magnesium stearate;
Further the preferred weight proportioning is: 330～380 parts of Radix Astragali extracts, 75～110 parts of microcrystalline Cellulose, 70～110 parts of carboxymethyl starch sodium, 10～15 parts of crospolyvinylpyrrolidone, 3～7 parts of magnesium stearate;
Most preferably weight proportion is: 360 parts of Radix Astragali extracts, 90 parts of microcrystalline Cellulose, 100 parts of carboxymethyl starch sodium, 10 parts of crospolyvinylpyrrolidone, 5 parts of magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310302568.4A CN103385913B (en) | 2013-07-18 | 2013-07-18 | Radix Astragali extract and its preparation method and preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310302568.4A CN103385913B (en) | 2013-07-18 | 2013-07-18 | Radix Astragali extract and its preparation method and preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103385913A true CN103385913A (en) | 2013-11-13 |
| CN103385913B CN103385913B (en) | 2015-04-15 |
Family
ID=49530448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310302568.4A Active CN103385913B (en) | 2013-07-18 | 2013-07-18 | Radix Astragali extract and its preparation method and preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103385913B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103385913B (en) * | 2013-07-18 | 2015-04-15 | 成都标典生物科技开发有限公司 | Radix Astragali extract and its preparation method and preparation |
| CN104784248A (en) * | 2015-04-21 | 2015-07-22 | 四川国康药业有限公司 | Astragalus membranaceus extract, astragalus membranaceus tablet and preparation method thereof |
| CN107126555A (en) * | 2017-04-28 | 2017-09-05 | 安徽生物肽产业研究院有限公司 | A kind of pigskin collagen small peptide active component composition of wound healing |
| CN108451926A (en) * | 2018-04-28 | 2018-08-28 | 四川国康药业有限公司 | A kind of Radix Astragali pellet and preparation method thereof for invigorating qi for strengthening superficies |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1839920A (en) * | 2005-02-06 | 2006-10-04 | 成都地奥九泓制药厂 | Astragaloside injection and preparation method thereof |
| CN101130802A (en) * | 2007-07-30 | 2008-02-27 | 金凤燮 | Method for preparing astragaloside iv by enzymic hydrolysis for astragalus saponin glycosyl |
| CN101812109A (en) * | 2009-02-25 | 2010-08-25 | 罗河生 | Preparation method of astragaloside |
| CN103073614A (en) * | 2013-01-22 | 2013-05-01 | 西安岳达植物科技有限公司 | Method for extracting high-purity astragaloside from astragalus mongholicus |
| CN103550285A (en) * | 2013-11-06 | 2014-02-05 | 劲牌有限公司 | Astragalus extractive grading preparation method |
| CN103623039A (en) * | 2012-08-20 | 2014-03-12 | 上海医药工业研究院 | Astragaloside extract product, preparing method therefor and quality standard control method therefor |
| CN103675120A (en) * | 2013-11-15 | 2014-03-26 | 陕西白云制药有限公司 | Method for detecting effective components of Bishitong-branded crossostephium leaf slice |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103385913B (en) * | 2013-07-18 | 2015-04-15 | 成都标典生物科技开发有限公司 | Radix Astragali extract and its preparation method and preparation |
-
2013
- 2013-07-18 CN CN201310302568.4A patent/CN103385913B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1839920A (en) * | 2005-02-06 | 2006-10-04 | 成都地奥九泓制药厂 | Astragaloside injection and preparation method thereof |
| CN101130802A (en) * | 2007-07-30 | 2008-02-27 | 金凤燮 | Method for preparing astragaloside iv by enzymic hydrolysis for astragalus saponin glycosyl |
| CN101812109A (en) * | 2009-02-25 | 2010-08-25 | 罗河生 | Preparation method of astragaloside |
| CN103623039A (en) * | 2012-08-20 | 2014-03-12 | 上海医药工业研究院 | Astragaloside extract product, preparing method therefor and quality standard control method therefor |
| CN103073614A (en) * | 2013-01-22 | 2013-05-01 | 西安岳达植物科技有限公司 | Method for extracting high-purity astragaloside from astragalus mongholicus |
| CN103550285A (en) * | 2013-11-06 | 2014-02-05 | 劲牌有限公司 | Astragalus extractive grading preparation method |
| CN103675120A (en) * | 2013-11-15 | 2014-03-26 | 陕西白云制药有限公司 | Method for detecting effective components of Bishitong-branded crossostephium leaf slice |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103385913B (en) * | 2013-07-18 | 2015-04-15 | 成都标典生物科技开发有限公司 | Radix Astragali extract and its preparation method and preparation |
| CN104784248A (en) * | 2015-04-21 | 2015-07-22 | 四川国康药业有限公司 | Astragalus membranaceus extract, astragalus membranaceus tablet and preparation method thereof |
| CN104784248B (en) * | 2015-04-21 | 2019-01-18 | 四川国康药业有限公司 | A kind of Astragalus Root P.E, astragalus mongholicus tablet and preparation method thereof |
| CN107126555A (en) * | 2017-04-28 | 2017-09-05 | 安徽生物肽产业研究院有限公司 | A kind of pigskin collagen small peptide active component composition of wound healing |
| CN108451926A (en) * | 2018-04-28 | 2018-08-28 | 四川国康药业有限公司 | A kind of Radix Astragali pellet and preparation method thereof for invigorating qi for strengthening superficies |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103385913B (en) | 2015-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600219B (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
| CN100475243C (en) | Hypoglycemic, antilipenic and hemopathy-treating glutinous rehmannia extract and preparing method thereof | |
| CN103385913B (en) | Radix Astragali extract and its preparation method and preparation | |
| CN108250320A (en) | A kind of low ash content ganoderan extract and preparation method thereof | |
| CN102805767B (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN102070726B (en) | Method for safely extracting cordyceps sinensis polysaccharide | |
| CN112294830B (en) | American ginseng leaf product rich in rare ginsenoside | |
| CN109632980A (en) | Method and application thereof that is a kind of while detecting uridine and ergosterol | |
| CN1977885B (en) | Antihepatitis medicinal composition | |
| CN102357131B (en) | Method for preparing astragalus polysaccharide glucose-lowering capsule | |
| CN101342230A (en) | Radix astragali particle and quality control method thereof | |
| CN108057064B (en) | Corydalis tuber total alkaloid gastric floating tablet | |
| CN101766664A (en) | Extraction method of total saponin of Radix Ilicis Asprellae and quality detection method thereof | |
| CN104784248A (en) | Astragalus membranaceus extract, astragalus membranaceus tablet and preparation method thereof | |
| CN102342986B (en) | Active fraction in rose odorata sweet vat.gogantea(coll.et hemsl.)rehd.et wils for treating diarrhea and preparation method thereof | |
| CN103923042A (en) | Preparation method for salvianolic acid B extract | |
| CN103585208A (en) | Preparation method of high-quality andrographolide component | |
| CN113322298A (en) | Biological limit value determination method for Qingjin phlegm-resolving decoction | |
| CN102631441B (en) | Separation and purification method of total saponins of sanguisorba officinalis | |
| CN105503993A (en) | Preparation method and application of nigella damascena saponin A | |
| CN112076151A (en) | A Chinese medicinal oral liquid for treating diabetes due to deficiency of both qi and yin, and its preparation method and quality control method | |
| CN101176755B (en) | Application of meletin-7-0-glycoside in mass control of cudrania tricuspidata or preparations thereof | |
| CN105168280B (en) | A kind of antineoplastic solid first Microdot Capsule | |
| CN103585469B (en) | A kind of gymnadenia conopsea medicinal composition and its preparation method and application | |
| CN101229204A (en) | Process for preparing bupleurum total saponin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170517 Address after: Tongcheng road in Qingyang District of Chengdu City, Sichuan province 610072 8 No. 12 Building 1 unit 4 floor No. 1 Patentee after: Sichuan Zhiqiang Pharmaceutical Technology Development Co., Ltd. Address before: 610000, No. 5, building 16, 1 prosperous West Road, 2, Sichuan, Chengdu, Jinniu District Patentee before: Chengdu Biaodian Biological Science & Technology Development Co., Ltd. |